|
|
|
|
| LEADER |
01843nam a2200313 u 4500 |
| 001 |
EB001865342 |
| 003 |
EBX01000000000000001029422 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
190504 r ||| eng |
| 100 |
1 |
|
|a Seal, Kelsey
|
| 245 |
0 |
0 |
|a BRAF targeted therapy after immunotherapy for patients with metastatic melanoma
|h Elektronische Ressource
|b a review of clinical effectiveness
|c Kelsey Seal, Lorna Adcock
|
| 250 |
|
|
|a Version 1.0
|
| 260 |
|
|
|a Ottawa (ON)
|b Canadian Agency for Drugs and Technologies in Health
|c 2017, October 18, 2017
|
| 300 |
|
|
|a 1 PDF file (20 pages)
|b illustrations
|
| 505 |
0 |
|
|a Includes bibliographical references
|
| 653 |
|
|
|a Melanoma / secondary
|
| 653 |
|
|
|a Immunotherapy
|
| 653 |
|
|
|a Melanoma / therapy
|
| 653 |
|
|
|a Treatment Outcome
|
| 653 |
|
|
|a Proto-Oncogene Proteins B-raf / antagonists & inhibitors
|
| 700 |
1 |
|
|a Adcock, Lorna
|e [author]
|
| 710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a CADTH rapid response report: summary with critical appraisal
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK525603
|3 Volltext
|n NLM Bookshelf Books
|3 Volltext
|
| 082 |
0 |
|
|a 610
|
| 520 |
|
|
|a While the current pCODR Expert Review Committee (pERC) recommendations mainly focus on the use of immunotherapies and BRAF inhibitors (BRAFi) as first-line therapies, the optimal sequencing of BRAF targeted therapy and immunotherapy when both are considered for the treatment of advanced melanoma has yet to be determined. The purpose of this report is to evaluate the clinical effectiveness of BRAF targeted therapy in patients with BRAF mutation positive unresectable or metastatic melanoma who have received immunotherapy as their first-line option
|